{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-091799","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.403044+00:00","generated_at":"2026-05-31T12:21:19.779070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR","bullets":["Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.","Cash, cash equivalents and marketable securities of $239.1M as of June 30, 2024.","Interim Phase 1b/2 data for palazestrant + ribociclib showed 85% clinical benefit rate in 13 evaluable patients.","IND for KAT6 inhibitor OP-3136 expected to be filed with FDA in late 2024; pre-clinical data in Q4.","Plan to initiate Phase 1b/2 study of palazestrant + everolimus in Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-091799","json":"https://secwatch.observer/filing/0000950170-24-091799.json","markdown":"https://secwatch.observer/filing/0000950170-24-091799.md","text":"https://secwatch.observer/filing/0000950170-24-091799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024091799/0000950170-24-091799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017024091799/olma-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:21:19.779070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}